IL2 and neoplasm: In our studies, while modest direct anti-tumor effects were obtained using this approach, combination of MRF/magnetic field treatment with immunotherapy using suboptimal doses of agonistic anti-CD40/IL2 resulted in significantly greater and, importantly, systemic anti-tumor responses.